Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002
The effectiveness of inhaled steroids by metered dose inhaler with aerochamber and face mask for children ages 6 months to 4 years Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
Formoterol 6 μg and 12 μg delivered via a new multi-dose dry powder inhaler has a rapid onset of action with a duration of at least 12 hours Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008
Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Efficacy and tolerability of formoterol Turbuhaler in 6–11 year old children with asthma, not adequately controlled with inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002
Budesonide 800 μg/day via Easyhaler® is as safe and effective as the same dose of budesonide via Turbuhaler® in adult asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 208s Year: 2006
Budesonide and formoterol in a single inhaler is safe and effective in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old Source: Eur Respir J 2003; 22: Suppl. 45, 535s Year: 2003
Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Evaluation of long-term safety, growth and efficacy of fluticasone propionate 100mcg bd compared with sodium cromoglycate 5mg qds in asthmatic children aged 12-47 months Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002